Drug Profile
CT P27
Alternative Names: CT-P27; Universal influenza antibody - CelltrionLatest Information Update: 07 Nov 2022
Price :
$50
*
At a glance
- Originator Celltrion
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Influenza virus fusion inhibitors; Influenza virus haemagglutinin glycoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza A virus infections
Most Recent Events
- 31 Oct 2022 Celltrion terminates a phase-II trials in Influenza A virus infections in South Korea (IV) (KCT0002211) (NCT03511066)
- 25 Sep 2020 CT P27 is still in development for Influenza A virus infections in South Korea (Celltrion website, September 2020)
- 13 Apr 2019 Efficacy and adverse events data from a phase IIb trial in Influenza A virus infections presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2019)